Drug intelligence / Profile preview

SARS-CoV-2 vaccine (Beijing 302 Hospital)

Development stage
Unknown
Lead developer
The Fifth Medical Center of the PLA General Hospital
Modality
Vaccines & Immunotherapeutics
Administration
Intramuscular
01

Overview

SARS-CoV-2 vaccine (Beijing 302 Hospital) refers to a vaccine candidate or vaccination regimen developed and clinically evaluated by the Beijing 302 Hospital (also known as the Fifth Medical Center of the PLA General Hospital). The vaccine is primarily associated with clinical research into heterologous prime-boost strategies for COVID-19. Specifically, it has been studied in Phase 1/2 trials to assess safety and immunogenicity in high-risk populations, such as patients with various stable cancers who have previously received a primary vaccination series. The vaccine aims to elicit a robust immune response against the SARS-CoV-2 virus to prevent infection and reduce disease severity, particularly in individuals who may have a diminished response to standard vaccination protocols.

Other names
Beijing 302 Hospital COVID-19 vaccineBeijing302 Hospital COVID-19 vaccineBeijing-302 Hospital COVID-19 vaccineFifth Medical Center of the PLA General Hospital COVID-19 vaccineCoronavirus vaccination
02

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on SARS-CoV-2 vaccine (Beijing 302 Hospital).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on SARS-CoV-2 vaccine (Beijing 302 Hospital).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call